How PMPRB Regulates New Drug Prices: Will Changes Help or Hurt Access?
FORMAT: Panel Debate with Discussion
Proposed amendments to Patented Medicines Regulations to allow for key changes to determining the Maximum List Price of prescription medicines will result in lower Canadian prices with no loss in Canadian access new medicines.
Canadians’ ability to access to new medicines will be severely impacted by the proposed PMPRB Price Review, which applies, among other factors, a single “cost-effectiveness” threshold on the Maximum List Price of all new medicines, an approach not used by any other country.
National Pharmacare and PMPRB must assure that Canada improves, not worsen, its ability to attract clinical trials and innovative medicines; we should consider processes like “managed entry” as used Sweden, Germany, and the UK where initial (entry) prices are modified afterwards based on “real world” evidence of effectiveness.
Information on how to register for the webinar and other details will be announced shortly.
This is one of six webinars in a National Pharmacare Debate series hosted by CORD.
For the complete list of webinars in this series, click here.